Clinical Trial Update: A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of Tulisokibart (MK-7240/PRA023) in moderately to severely active ulcerative colitis completed, with results posted on 2024-06…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Tulisokibart (MK-7240/PRA023) (MK-7240/PRA023)

Snippet

Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Ulcerative Colitis | Phase 2 | Status: COMPLETED | Results posted: 2024-06-27